Merkel Cell Carcinoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Merkel Cell Carcinoma Pipeline Drugs Market Report Overview
Merkel cell carcinoma is a rare aggressive skin cancer that is at high risk of recurring and spreading (metastasizing) throughout the body. Symptom includes painless nodule on the skin. It usually starts on areas of skin exposed to the sun (face, neck, arms, and legs). Treatment includes chemotherapy, radiation therapy and surgery.
The Merkel Cell Carcinoma pipeline drugs market research report provides comprehensive information on the therapeutics under development for Merkel Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for Merkel Cell Carcinoma and features dormant and discontinued projects.
Merkel Cell Carcinoma Pipeline Drugs Market Segmentation by Targets
The key targets in the Merkel Cell Carcinoma pipeline drugs market are Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Cytotoxic T Lymphocyte Protein 4, E3 Ubiquitin Protein Ligase Mdm2, and others. Programmed Cell Death Protein 1 has the highest number of products in development in the Merkel Cell Carcinoma pipeline drugs market.
Merkel Cell Carcinoma Pipeline Drugs Market Analysis by Targets
For more target insights into the Merkel Cell Carcinoma pipeline drugs market, download a free report sample
Merkel Cell Carcinoma Pipeline Drugs Market Segmentation by Mechanisms of Action
The key mechanisms of action in the Merkel Cell Carcinoma pipeline drugs market Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, E3 Ubiquitin Protein Ligase Mdm2 Inhibitor, and others. Programmed Cell Death Protein 1 Antagonist leads the Merkel Cell Carcinoma pipeline drugs market in terms of MoA.
Merkel Cell Carcinoma Pipeline Drugs Market Analysis by Mechanisms of Action
For more MoA insights into the Merkel Cell Carcinoma pipeline drugs market, download a free report sample
Merkel Cell Carcinoma Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the Merkel Cell Carcinoma pipeline drugs market are intravenous, intratumor, subcutaneous, oral, and others. The intravenous RoA has the highest number of Merkel Cell Carcinoma drugs in development in 2022.
Merkel Cell Carcinoma Pipeline Drugs Market Analysis by Routes of Administration
For more RoA insights into the Merkel Cell Carcinoma pipeline drugs market, download a free report sample
Merkel Cell Carcinoma Pipeline Drugs Market Segmentation by Molecule Types
The key molecule types in the Merkel Cell Carcinoma pipeline drugs market are monoclonal antibody, small molecule, fusion protein, oncolytic virus, and others. Monoclonal antibody leads the Merkel Cell Carcinoma pipeline drugs market in terms of molecule type.
Merkel Cell Carcinoma Pipeline Drugs Market Analysis by Molecule Types
For more molecule type insights into the Merkel Cell Carcinoma drugs market, download a free report sample
Merkel Cell Carcinoma Pipeline Drugs Market - Competitive Landscape
Some of the leading companies in the Merkel Cell Carcinoma pipeline drugs market are Bristol-Myers Squibb Co, Aulos Bioscience Inc, F. Hoffmann-La Roche Ltd, ImmunityBio Inc, and Incyte Corp. Bristol-Myers Squibb Co has the highest number of Merkel Cell Carcinoma drugs in development in 2022.
Merkel Cell Carcinoma Pipeline Drugs Market Analysis by Companies
To know more about the leading Merkel Cell Carcinoma pipeline drugs market players, download a free report sample
Merkel Cell Carcinoma Pipeline Products Market Overview
Key Targets | Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Cytotoxic T Lymphocyte Protein 4, E3 Ubiquitin Protein Ligase Mdm2, and Others |
Key Mechanisms of Action | Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, E3 Ubiquitin Protein Ligase Mdm2 Inhibitor, and Others |
Key Routes of Administration | Intravenous, Intratumor, Subcutaneous, Oral, and Others |
Key Molecule Type | Monoclonal Antibody, Small Molecule, Fusion Protein, Oncolytic Virus, and Others |
Leading Companies | Bristol-Myers Squibb Co, Aulos Bioscience Inc, F. Hoffmann-La Roche Ltd, ImmunityBio Inc, Incyte Corp, and Others |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Merkel Cell Carcinoma.
- The pipeline guide reviews pipeline therapeutics for Merkel Cell Carcinoma by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Merkel Cell Carcinoma therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Merkel Cell Carcinoma therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Merkel Cell Carcinoma
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Merkel Cell Carcinoma.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding the Merkel Cell Carcinoma pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.
Aileron Therapeutics Inc
Alphamab Oncology
Alpine Immune Sciences Inc
Amgen Inc
Apcure SAS
Arcus Biosciences Inc
Aulos Bioscience Inc
Bavarian Nordic AS
BeiGene Ltd
Beijing Advaccine Biotechnology Company Ltd
BeyondSpring Inc
BioInvent International AB
Biosion Inc
Boston Pharmaceuticals Inc
Bristol-Myers Squibb Co
CanWell Pharma Inc
Centrymed Pharmaceutical Inc
Checkpoint Therapeutics Inc
Codiak BioSciences Inc
CStone Pharmaceuticals Co Ltd
CytomX Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Co
Exelixis Inc
F-star Therapeutics Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Fujifilm Holdings Corp
Genexine Inc
GI Innovation Co Ltd
Guangzhou Yinming Biomedical Technology Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
ImmunityBio Inc
Immunomic Therapeutics Inc
Incyte Corp
JSR Life Sciences LLC
Kartos Therapeutics Inc
Medicenna Therapeutics Corp
Memgen Inc
Merck & Co Inc
Merck KGaA
Morphogenesis Inc
Novartis AG
Ocellaris Pharma Inc
OncoSec Medical Inc
Oncovir Inc
Ono Pharmaceutical Co Ltd
Pfizer Inc
Philogen SpA
PokeAcell
QBiotics Group Ltd
Regeneron Pharmaceuticals Inc
Replimune Ltd
Seven and Eight Biopharmaceuticals Corp
Simcha Therapeutics Inc
SOTIO Biotech AS
Tarveda Therapeutics Inc
Treadwell Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Merkel Cell Carcinoma pipeline drugs market?
The key targets in the Merkel Cell Carcinoma pipeline drugs market are Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Cytotoxic T Lymphocyte Protein 4, E3 Ubiquitin Protein Ligase Mdm2, and others.
-
What are the key mechanisms of action in the Merkel Cell Carcinoma pipeline drugs market?
The key MoA in the Merkel Cell Carcinoma pipeline drugs market are Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, E3 Ubiquitin Protein Ligase Mdm2 Inhibitor, and others.
-
What are the key routes of administration in the Merkel Cell Carcinoma pipeline drugs market?
The key RoA in the Merkel Cell Carcinoma pipeline drugs market are intravenous, intratumor, subcutaneous, oral, and others.
-
What are the key molecule types in the Merkel Cell Carcinoma pipeline drugs market?
The key molecule types in the Merkel Cell Carcinoma pipeline drugs market are monoclonal antibody, small molecule, fusion protein, oncolytic virus, and others.
-
Which are the leading companies in the Merkel Cell Carcinoma pipeline drugs market?
Some of the leading companies in the Merkel Cell Carcinoma pipeline drugs market are Bristol-Myers Squibb Co, Aulos Bioscience Inc, F. Hoffmann-La Roche Ltd, ImmunityBio Inc, and Incyte Corp.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.